Development of high-performance magnetic chemiluminescence enzyme immunoassay for alpha-fetoprotein (AFP) in human serum

Detection of serum CC16 by a rapid and ultrasensitive magnetic chemiluminescence immunoassay for lung disease diagnosis

OBJECTIVES

It has been reported that serum Clara cell secreted protein 16 (CC16) is a potential biomarker for lung injury diseases, but currently, there is no other method that is faster, more accurate, or more sensitive being applied in clinical practice apart from ELISA. The current study was designed to established a magnetic nanoparticles chemiluminescence immunoassay (MNPs-CLIA) for highly sensitive automated detection of serum Clara cell secretory protein 16 (CC16), and validated its diagnostic performance for lung disease.

METHODS

The study included the expression of CC16 recombinant protein, the preparation and screening of its monoclonal antibody (MAb), as well as the construction, optimization and analytical evaluation of the MNPs-CLIA method. The clinical application value of this method was investigated by detecting CC16 level in 296 serum samples.

RESULTS

The linear range of the MNPs-CLIA assay system was 0.2-50 ng/mL, and the limit of detection was 0.037 ng/mL. Performance parameters such as specificity, recovery rate, and precision can meet the industry standards of in vitro diagnostic reagents. The established method reveals consistent results with ELISA (R2=0.9962) currently used clinically, and it also exhibits satisfactory diagnostic efficacy of silicosis, chronic obstructive pulmonary disease (COPD), and pulmonary sarcoidosis, with areas under the curve (AUC) of 0.9748, 0.8428 and 0.9128, respectively.

CONCLUSIONS

Our established MNPs-CLIA method has the advantages of automation, high throughput, rapidity, and simplicity, and can be promoted for widely popularized in clinical applications. MNPs-CLIA detection of serum CC16 has efficient diagnostic potentiality for predicting and diagnosing lung diseases.

A new method for broadening the detection range of immunoassay and its application in β-hCG quantitative detection

Early pregnancy prediction requires very high β-hCG detection sensitivity, while embryonic development monitoring and trophoblastic disease detection require a wider detection range. In this study, based on light-initiated chemiluminescence assay (LICA), one high-affinity mAb and one low-affinity mAb were selected and coated on chemibeads with a larger coating area in different ratios to immobilize the antibodies. The two immobilized mAbs were mixed with different concentrations to detect β-hCG. When the high-affinity mAb-coated chemibeads and low-affinity mAb-coated chemibeads were used at working concentrations of 0.100 mg mL^-1 and 0.014 mg mL^-1, respectively, the sensitivity and detection range were maximized. The assay was precise for measuring β-hCG with repeatability and intermediate precision of <5% CV. The assay has a high sensitivity with a limit of quantification (LoQ) of 0.49 IU L^-1, which is lower than that of most β-hCG detection kits. Over the range of 1 IU L^-1 to 16 000 IU L^-1, the assay had a proper linearity (r = 0.9995). No false negative results due to the hook effect were observed at β-hCG concentrations up to 225 000 IU L^-1. The assay showed a good correlation with the Abbott assay (r = 0.9910). LICA combined with immobilized mAbs with different affinities ensures the sensitivity of β-hCG detection and broadens the detection range.

High sensitivity silicon nanowire array sensor for joint detecting the tumor markers CEA and AFP

Liver cancer is one of the malignant tumors with the highest fatality rate and the increasing incidence, which has no effective treatment plan. Early diagnosis and early treatment of liver...

Selection and characterization of a novel affibody peptide and its application in a two-site ELISA for the detection of cancer biomarker alpha-fetoprotein

Alpha-fetoprotein (AFP) is one of the most important biomarkers associated with primary liver cancer, and the main approaches for diagnosis are based on immunoassay. Affibody is a 58 amino acids peptide derived from the Z domain of staphylococcal protein A and generally applied in imaging diagnosis, clinical therapeutics and biotechnology research. The aim of this study was therefore to develop a novel affibody-based ELISA for detection of AFP. After three rounds of biopanning, six AFP-binding affibody peptides were selected using phage display technology, among them affibody Z_AFPD2 showed high and specific binding affinity to AFP. An affibody dimer of Z_AFPD2 was created, named (Z_{AFP D2})₂, expressed in E.coli and the purified (Z_{AFP D2})₂ recombinant protein showed higher binding affinity to AFP, as well as high thermal stability. A novel affibody-based two-site ELISA method using Z_AFPD2 or (Z_{AFP D2})₂ and polyclonal antibody to detect AFP was developed, the detection limit of the immunoassay using (Z_{AFP D2})₂ was 2 ng mL^-1 that was 4 times lower than Z_AFPD2, which meets the requirements for practical application. Therefore, this concept of affibody-based ELISA may provide a new method for the detection of various cancer biomarkers.

Fluorescence sensing strategy based on aptamer recognition and mismatched catalytic hairpin assembly for highly sensitive detection of alpha-fetoprotein

At present, alpha fetoprotein (AFP) is mainly used as a serum marker of primary Hepatocellular carcinoma. A simple, enzyme-free sensing strategy is introduced for highly sensitive fluorescence detection of AFP. This detection strategy is based on aptamer recognition and mismatched catalytic hairpin assembly (MCHA). At first, Trigger is locked by aptamer before the introduction of AFP in this aptamer-MCHA system. The aptamer preferentially combines with AFP via powerful attraction in the presence of AFP. This results in the release of trigger and initiation of MCHA cycle, thus forming the H1 and H2 double chain complexes (denoted as H1@H2). Finally, H1@H2 and double chain structure containing fluorophore and its quenched group- BHQ1 (denoted as F@Q) initiated displacement reaction, which caused double chain separation and fluorescence recovery. This assay produces a wide detection range, which is from 0.1 ng mL^-1 to 10 μg mL^-1 and the limit of detection as 0.033 ng mL^-1. The whole detection process was performed at 37 °C for 60 min. In addition, this assay had high anti-interference ability and could be used to detect AFP in clinical serum. This novel AFP detection strategy is able to screen of Hepatocellular carcinoma.

A chemiluminescence immunoassay for rapid detection of classical swine fever virus E2 antibodies in pig serum samples

The high performance of chemiluminescence immunoassays (CLIAs) in diagnosis has been gradually recognized in recent years, but their application in the diagnosis of classical swine fever (CSF) has not been reported. Here, a recombinant E2 (rE2) protein and a peroxidase-conjugated monoclonal antibody (MAb G5) were used to develop a competition-based chemiluminescence immunoassay (cCLIA) for rapid and accurate detection of E2-specific antibodies in pig serum. To evaluate the feasibility of cCLIA in the diagnosis of CSF, we developed a competition-based enzyme-linked immunosorbent assay (cELISA) as a control. Under the optimum test conditions, cCLIA showed a higher signal-to-noise ratio than that of the control cELISA. The best signal-to-noise ratios of cCLIA and cELISA were 70 and 17, respectively. Then, the diagnostic performance of the two assays was compared by examining a panel of pig serum samples (n = 285) with a confirmed status, and cCLIA showed higher diagnostic sensitivity (Dn) and diagnostic specificity (Dp) values than those of cELISA. The Dn and Dp of cCLIA were 97.49% and 96.08%, respectively, and those of cELISA were 93.97% and 94.12%, respectively. Furthermore, cCLIA can provide results within 20 min, whereas the control cELISA requires at least 1 hr. According to these findings, the newly developed cCLIA has potential application in the diagnosis of CSF and offers an alternative approach for efficient and rapid detection of E2-specific antibodies.

An ultrasensitive chemiluminescence immunoassay for fumonisin B1 detection in cereals based on gold-coated magnetic nanoparticles

BACKGROUND

In the present study, a novel highly sensitive magnetic enzyme chemiluminescence immunoassay (MECLIA) was developed to detect fumonisin B₁ (FB₁ ) in cereal samples. The gold-coated magnetic nanoparticles (Fe₃ O₄ @Au, GoldMag) were used as solid phase carrier to develop a competitive CLIA for detecting FB₁ , in which FB₁ in samples would compete with FB₁ -ovalbumin coated on the surface of Fe₃ O₄ @Au nanoparticles for binding with FB₁ antibodies. Successively, horseradish peroxidase labeled goat anti-rabbit IgG (HRP-IgG) was conjugated with FB₁ antibodies on the microplate. In substrate solution containing luminol and H₂ O₂ , HRP-IgG catalyzed luminol oxidation by H₂ O₂ , generating a high chemiluminescence signal. The FB₁ immune GoldMag particles were characterized by Fourier transform infrared spectroscopy, scanning electron microscope and zeta potential analysis, etc. RESULTS: The concentrations and the reaction times of these immunoreagents were optimized to improve the performances of this method. The established method could detect as low as 0.027 ng mL^-1 FB₁ from 0.05 ng mL^-1 to 25 ng mL^-1 , demonstrating little cross-reaction (less than 2.4%) with other structurally related compounds. The average intrassay relative SD (RSD) (n = 6) was 3.4% and the average interassay RSD (n = 6) was 5.4%. This method was successfully applied for the determination of FB₁ in corn and wheat and gave recoveries of between 98-110% and 91-105%, respectively.

CONCLUSION

The results of the present study suggest that the MECLIA approach has potential application for high-throughput fumonisin screening in cereals. © 2018 Society of Chemical Industry.

Detection of urinary survivin using a magnetic particles-based chemiluminescence immunoassay for the preliminary diagnosis of bladder cancer and renal cell carcinoma combined with LAPTM4B

The aim of the present study was to establish a simple step magnetic particles (MPs) based chemiluminescence enzyme immunoassay (CLEIA) for the detection of urinary survivin, and to investigate the diagnostic value of urinary survivin and lysosome-associated protein transmembrane-4β (LAPTM4B) in bladder cancer (BC) and renal cell carcinoma (RCC). The MPs-based CLEIA was developed on the basis of a double antibodies sandwich immunoreaction and luminol-H₂O₂ chemiluminescence system. The parameters of the method were optimized and evaluated. Urine samples were obtained from 200 BC patients, 81 RCC patients and 114 healthy individuals, and the MPs-based CLEIA method was employed to detect their urinary survivin. At the same time, the urinary LAPTM4B levels of the BC patients, RCC patients and the healthy controls were measured. The diagnostic efficiency of urinary survivin and LAPTM4B in BC and RCC was evaluated separately and jointly. A one-step MPs-based CLEIA for the detection of urinary survivin with good accuracy and precision was established. The signals were dependent on survivin concentrations in the range, 0 to 200 ng/ml, and the detection limit was 0.949 ng/ml. The areas under the receiver operating characteristic curves (AUC) were 0.771 in BC and 0.763 in RCC for urinary survivin. Urinary survivin was correlated with the tumor stage (P=0.002), lymph node metastasis (P=0.017), distant metastasis (P=0.005) and tumor size (P=0.02) of BC; however, no association with the clinicopathological parameters in RCC was observed. The AUCs for urinary LAPTM4B were 0.738 in BC and 0.704 in RCC, respectively. The AUCs for them combined were 0.842 in BC and 0.920 in RCC. The MPs-based CLEIA was performed well in the detection of urinary survivin. Urinary survivin and LAPTM4B could serve as potential biomarkers for the preliminary diagnosis of BC and RCC, and in combination they a achieved a greater diagnostic performance.

A magnetic nanoparticle-labeled immunoassay with europium and samarium for simultaneous quantification of serum pepsinogen I and II

OBJECTIVE

To develop a novel immunoassay for the simultaneous determination of serum pepsinogen I (PG I) and pepsinogen II (PG II) by combining established methods of time-resolved fluoroimmunoassay (TRFIA) and magnetic nanoparticles separation.

MATERIALS AND METHODS

This new immunoassay method was characterised by immobilising primary antibodies on the surface of magnetic particles and labelled with stable fluorescent chelates of europium and samarium.

RESULTS

Using magnetic nanoparticles, the TRFIA immunoassay exhibited broad dynamic assay ranges for PG I with detection limit of 0.33 ng/mL, while for PG II with detection limit of 0.38 ng/mL. Cross-reactivity between PGs I and II were <15. The intra- and inter-assay coefficient variations of the method were <3%, and the recoveries were in the range of 97-103% for serum samples. Bland-Altman analysis of 124 serum samples showed good consistency with a commercial TRFIA kit. For PG I, the mean (95% confidence interval) difference was 0.97 (-14.3-12.3) ng/mL, whilst for PG II the difference was 0.6 (-4.4-3.2) ng/mL.

CONCLUSIONS

Our data suggest that the method is feasible and could be developed into a platform for the routine clinical determination of PG I and PG II levels in human serum.

A sensitive label-free immunosensor for detection α-Fetoprotein in whole blood based on anticoagulating magnetic nanoparticles

Accurate values of tumor markers in blood play an especially important role in the diagnosis of illness. Here, based on the combination of three techniques include anticoagulant technology, nanotechnology and biosensing technology, a sensitive label-free immunosensor with anti-biofouling electrode for detection α-Fetoprotein (AFP) in whole blood was developed by anticoagulating magnetic nanoparticles. The obtained products of Fe₃O₄-ɛ-PL-Hep nanoparticles were characterized by fourier transform infrared (FT-IR) spectra, transmission electron microscopy (TEM), ζ-potential and vibrating sample magnetometry (VSM). Moreover, the blood compatibility of anticoagulating magnetic nanoparticles was characterized by in vitro coagulation tests, hemolysis assay and whole blood adhesion tests. Combining the anticoagulant property of heparin (Hep) and the good magnetism of Fe₃O₄, the Fe₃O₄-ɛ-PL-Hep nanoparticles could improve not only the anti-biofouling property of the electrode surface when they contact with whole blood, but also the stability and reproducibility of the proposed immunosensor. Thus, the prepared anticoagulating magnetic nanoparticles modified immunosensor for the detection of AFP showed excellent electrochemical properties with a wide concentration range from 0.1 to 100ng/mL and a low detection limit of 0.072ng/mL. Furthermore, five blood samples were assayed using the developed immunosensor. The results showed satisfactory accuracy with low relative errors. It indicated that our developed immunoassay was competitive and could be potentially used for the detection of whole blood samples directly.

Multiplexed detection of pathogen-specific DNA using engineered zinc finger proteins without target amplification

Multiplexed detection of pathogen-specific DNA sequences in a simple and reliable way is in great demand for clinical and biomedical applications. However, there is still a lack of available DNA detection methods that are simple and pathogen-selective for point-of-care (POC) testing. Here, we report a novel zinc finger protein (ZFP)-based chemiluminescent method for direct detection of pathogenic double-stranded DNA (dsDNA) in a multiplexed platform. ZFPs are custom-designed to identify unique pathogenic DNA sequences. ZFP-based chemiluminescent detection of dsDNA provides sufficient sensitivity (≤50 fmol) and high specificity without target DNA amplification. Our study addresses the potential of developing a simple and selective pathogen detection method in a multiplexed fashion needed for POC application.

An optionality further amplification of an sandwich-type electrochemical immunosensor based on biotin–streptavidin–biotin strategy for detection of alpha fetoprotein

An optionality further amplification of sandwich-type electrochemical immunosensor based on biotin–streptavidin–biotin strategy.

Establishment of Magnetic Microparticles-Assisted Time-Resolved Fluoroimmunoassay for Determinating Biomarker Models in Human Serum

In order to early screen and detect suspected biomarkers from pathogens and the human body itself, tracers or reaction strategies that can act as signal enhancers have been proposed forth at purpose. In this paper, we discussed the applicability of magnetic microparticles-assisted time-resolved fluoroimmunoassay (MMPs-TRFIA) for sensitive determination of potential analytes. Hepatitis B e antigen, antibody to hepatitis B surface antigen and free triiodothyronine were used as biomarker models to explore the reliability of the method. By coupling with bioprobes, MMPs were used as immunoassay carriers to capture target molecules. Under optimal condition, assay performance, including accuracy, precision and specificity, was outstanding and demonstrated satisfactory. To further evaluate the performance of the MMPs-TRFIA in patients, a total of 728 serum samples from hospital were analyzed for three biomarkers in parallel with the proposed method and chemiluminescence immunoassay kit commercially available. Fairly good agreements are obtained between the two methods via data analysis. Not only that but the reliability of MMPs-TRFIA has also been illustrated by three different reaction models. It is confirmed that the novel method modified with MMPs has been established and showed great potential applications in both biological detection and clinical diagnosis, including big molecule protein and low molecular weight haptens.

Evaluation of a magnetic particles-based chemiluminescence enzyme immunoassay for Golgi protein 73 in human serum

BACKGROUND

Golgi protein 73 (GP73) is regarded as a potential serum biomarker for early diagnosis of hepatocellular carcinoma (HCC). We developed a rapid magnetic particles-based chemiluminescence enzyme immunoassay (MPs-CLEIA) for the determination of serum GP73.

METHODS

Fluorescein isothiocyanate (FITC) and alkaline phosphatase (ALP) were used to label 2 different monoclonal antibodies to GP73. Serum GP73 was captured with labeled antibodies and formed a sandwiched immunoreaction. The magnetic particles (MPs) coated with anti-FITC antibody were used as a means of separation of the GP73 protein from other serum proteins. After adding the enzyme substrate solution, the relative light unit (RLU) was measured. A MPs-CLEIA for serum GP73 was established and evaluated.

RESULTS

The RLU was directly proportional to the concentration of GP73. The method linearity was 5-600 μg/l. Limit of the blank was 2.19 μg/l. The intra- and inter-assay imprecision was <3% and <5%, respectively. The average recoveries were between 95% and 105%. The proposed method showed a good correlation with a commercial ELISA assay (r=0.983, p<0.001). We also evaluated the efficiency of serum GP73 measurement for the diagnosis of HCC using this assay. The area under the receiver operating characteristic curve was 0.822 (95% CI, 0.73-0.89), and the sensitivity and specificity, with cut-off value of 115.6 μg/l, were 75.4% and 92.1%, respectively.

CONCLUSIONS

The proposed method demonstrates an acceptable performance for quantifying serum GP73. This assay could be appropriate for routine use in clinical laboratories.

Rapid immunoenzyme assay of aflatoxin B1 using magnetic nanoparticles

The main limitations of microplate-based enzyme immunoassays are the prolonged incubations necessary to facilitate heterogeneous interactions, the complex matrix and poorly soluble antigens, and the significant sample dilutions often required because of the presence of organic extractants. This study presents the use of antibody immobilization on the surface of magnetic particles to overcome these limitations in the detection of the mycotoxin, aflatoxin B1. Features of the proposed system are a high degree of nanoparticle dispersion and methodologically simple immobilization of the antibodies by adsorption. Reactions between the immobilized antibodies with native and labeled antigens are conducted in solution, thereby reducing the interaction period to 5 min without impairing the analytical outcome. Adsorption of immunoglobulins on the surface of magnetic nanoparticles increases their stability in aqueous-organic media, thus minimizing the degree of sample dilution required. Testing barley and maize extracts demonstrated a limit of aflatoxin B1 detection equal to 20 pg/mL and total assay duration of 20 min. Using this method, only the 3-fold dilution of the initial methanol/water (60/40) extraction mixture in the microplate wells is necessary. The proposed pseudo-homogeneous approach could be applied toward immunodetection of a wide range of compounds.

Glypican-3 antibody functionalized Prussian blue nanoparticles for targeted MR imaging and photothermal therapy of hepatocellular carcinoma

MRI-guided photothermal therapy is becoming a more widely accepted minimally invasive technique.

Simultaneous determination of the cytokeratin 19 fragment and carcinoembryonic antigen in human serum by magnetic nanoparticle-based dual-label time-resolved fluoroimmunoassay

A magnetic nanoparticle-based dual-label TRFIA employing europium and samarium chelate labels for simultaneous determination of CYFRA 21-1 and CEA.

Influence of the physical and chemical properties of magnetic nanoparticles on their performance in a chemiluminescence immunoassay

OBJECTIVES

Magnetic nanoparticles (MNPs) are important carriers in immunoassays. In this study, we investigated the influence of the physical and chemical properties of MNPs on their performance in a detection process.

DESIGN AND METHODS

A comparative study of the properties of two MNPs with sizes of 200nm and 1μm (MNP-200nm and MNP-1μm, respectively) was conducted using the following four aspects: nonspecific adsorption to proteins (IgG was used as a model protein), influence of magnetic nanoparticles on the chemiluminescence signal, response speed to an external magnetic field, and intensity of the detection signal.

RESULTS

MNP-1μm exhibited lower nonspecific adsorption to IgG in serum, a weaker interference with the chemiluminescence signal, and a higher response speed to the external magnetic field than the same amount of MNP-200nm. An automated chemiluminescence immunoassay system based on MNP-1μm was also established.

CONCLUSIONS

MNP-1μm acts as an excellent carrier in an automated chemiluminescence immunoassay system for the analysis of serum samples from clinical patients.

Comparison of chemiluminescence enzyme immunoassay based on magnetic microparticles with traditional colorimetric ELISA for the detection of serum α-fetoprotein

A chemiluminescence enzyme immunoassay based on magnetic microparticles (MmPs-CLEIA) was developed to evaluate serum α-fetoprotein (AFP) in parallel with traditional colorimetric enzyme-linked immunosorbent assay (ELISA). A systematic comparison between the MmPs-CLEIA and colorimetric ELISA concluded that the MPs-CLEIA exhibited fewer dosages of immunoreagents, less total assay time, and better linearity, recovery, precision, sensitivity and validity. AFP was detected in forty human serum samples by the proposed MPs-CLEIA and ELISA, and the results were compared with commercial electrochemiluminescence immunoassay (ECLIA) kit. The correlation coefficient between MPs-CLEIA and ELISA was obtained with R²=0.6703; however, the correlation between MPs-CLEIA and ECLIA (R²=0.9582) was obviously better than that between colorimetric ELISA and ECLIA (R²=0.6866).

Chemiluminescence enzyme immunoassay based on magnetic nanoparticles for detection of hepatocellular carcinoma marker glypican-3

Glypican-3 (GPC3) is reported as a great promising tumor marker for hepatocellular carcinoma (HCC) diagnosis. Highly sensitive and accurate analysis of serum GPC3 (sGPC3), in combination with or instead of traditional HCC marker alpha-fetoprotein (AFP), is essential for early diagnosis of HCC. Biomaterial-functionalized magnetic particles have been utilized as solid supports with good biological compatibility for sensitive immunoassay. Here, the magnetic nanoparticles (MnPs) and magnetic microparticles (MmPs) with carboxyl groups were further modified with streptavidin, and applied for the development of chemiluminescence enzyme immunoassay (CLEIA). After comparing between MnPs- and MmPs-based CLEIA, MnPs-based CLEIA was proved to be a better method with less assay time, greater sensitivity, better linearity and longer chemiluminescence platform. MnPs-based CLEIA was applied for detection of sGPC3 in normal liver, hepatocirrhosis, secondary liver cancer and HCC serum samples. The results indicated that sGPC3 was effective in diagnosis of HCC with high performance.